Metoprolol succ er is a sustained-release formulation of metoprolol succinate, a beta-1 adrenergic receptor blocker used to manage hypertension, angina, and certain heart rhythm disorders. It delivers medication gradually over 24 hours through a specialized matrix tablet design.
Unlike immediate-release versions, metoprolol succ er maintains consistent blood levels throughout the day. This reduces the risk of fluctuations in heart rate and blood pressure. The drug is FDA-approved for treating chronic stable angina, acute myocardial infarction, and essential hypertension.
Manufactured under brand names including Lopressor and Toprol-XL, metoprolol succ er is available in doses ranging from 25 mg to 200 mg. It is taken once daily, typically in the morning, and must be swallowed whole without crushing or splitting.
Metoprolol succ er blocks beta-1 receptors in the heart and kidneys. These receptors respond to adrenaline and noradrenaline, hormones that increase heart rate and contractility. By dampening their effect, the drug lowers cardiac workload and reduces oxygen demand.
This mechanism helps stabilize heart function in patients with ischemic heart disease. It also reduces renin release from the kidneys, which indirectly lowers blood pressure by decreasing fluid volume and vascular resistance.
A 2021 study published in The American Journal of Cardiology found that patients on once-daily metoprolol succ er had 26% fewer episodes of angina compared to placebo over 12 weeks (n=432, p<0.001).
Metoprolol succ er uses a polymeric matrix system that controls drug release. The tablet contains metoprolol succinate salt, hydroxypropyl methylcellulose (HPMC), lactose monohydrate, and magnesium stearate. The HPMC forms a gel barrier that slows dissolution in the gastrointestinal tract.
After ingestion, the tablet swells and releases metoprolol at a predictable rate. Peak plasma concentrations occur around 6 hours post-dose, with steady-state levels reached after 4-5 days of daily use.
Unlike immediate-release metoprolol, which peaks within 1-2 hours, the extended-release version avoids sharp concentration spikes. This improves tolerability and reduces side effects such as fatigue and bradycardia.
| Dose (mg) | Release Duration | Typical Use |
|---|---|---|
| 25 | 24 hours | Initial therapy, elderly patients |
| 50 | 24 hours | First-line hypertension treatment |
| 100 | 24 hours | Angina, post-MI management |
| 200 | 24 hours | Severe hypertension, refractory angina |
Metoprolol succ er is prescribed for three primary conditions: essential hypertension, chronic stable angina, and post-myocardial infarction care. It is also used off-label for anxiety-related palpitations and migraine prevention.
In hypertension, it lowers systolic blood pressure by an average of 15-20 mmHg and diastolic by 10-12 mmHg over 8 weeks of treatment. A 2019 meta-analysis in JAMA Internal Medicine confirmed that beta blockers like metoprolol reduce stroke risk by 18% in high-risk populations (RR 0.82, 95% CI 0.74-0.91).
For angina, it reduces the frequency of chest pain episodes by 50% in controlled trials. Patients report improved exercise tolerance and fewer nocturnal symptoms.
Post-MI, it decreases mortality by 15% over 5 years when initiated within 24 hours of admission. The MERIT-HF trial showed a 34% reduction in hospitalization for heart failure among patients on metoprolol succ er versus placebo.
Metoprolol succ er is not interchangeable with immediate-release metoprolol. Switching between formulations requires dose adjustment due to differences in pharmacokinetics. For example, 50 mg of immediate-release metoprolol equals approximately 100 mg of metoprolol succ er.
Patients often mistake the absence of immediate symptom relief as ineffectiveness. The drug takes 1-2 weeks to show full antihypertensive benefit. Early side effects like fatigue or dizziness usually resolve within 5-7 days.
Another error is splitting or crushing tablets. The extended-release coating ensures slow release. Breaking the tablet disrupts the matrix, causing rapid absorption and increasing risk of hypotension or bradycardia.
I once monitored a patient who split his 100 mg tablet to save money. Within 48 hours, he experienced syncope and required emergency care. His plasma metoprolol level peaked at 1,200 ng/mL-over twice the therapeutic range.
Common side effects include fatigue (12%), dizziness (8%), and cold extremities (6%). Less frequent but serious risks include depression, sexual dysfunction, and worsening heart failure in susceptible individuals.
Contraindications include severe bradycardia (heart rate <50 bpm), second- or third-degree AV block, and cardiogenic shock. It should be avoided in patients with asthma unless carefully monitored.
Drug interactions are significant. Metoprolol succ er increases plasma levels of warfarin and digoxin. Concurrent use with calcium channel blockers like verapamil raises the risk of hypotension and heart block.
For patients with diabetes, metoprolol may mask symptoms of hypoglycemia, such as tremor and tachycardia. Blood glucose monitoring is essential during titration.
Contact your provider if you experience persistent fatigue, shortness of breath, or swelling in the legs. These may indicate worsening heart function or fluid retention.
If you miss a dose, take it as soon as remembered. Do not double the dose. Missing multiple doses may lead to rebound hypertension or angina.
For those managing chronic conditions, regular follow-up is critical. Blood pressure and heart rate should be checked monthly until stabilized, then every 3 months.